SEC ownership of RECURSION PHARMACEUTICALS, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001601830.

Comparable stake leader

ARK Investment Management LLC

Disclosed value leader

ARK Investment Management LLC

Comparable rows

50/50

Latest evidence

15 May 2026

Top shareholders Insider holders Latest transactions

Public ticker: RXRX on Nasdaq
Parsed ownership sources: 13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: ARK Investment Management LLC
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: ARK Investment Management LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 15 May 2026
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001601830
Issuer location: Salt Lake City, UT

Ownership snapshot

Top shareholders of RECURSION PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

ARK Investment Management...

Disclosed value leader

ARK Investment Management...

Comparable rows

50/50

Latest evidence

15 May 2026

13D/G 13F 3/4/5 Lead comparable stake: 7.2% 13D/G row: ARK Investment Management LLC Showing 1-8 of 50 holder rows.

Quick read

ARK Investment Management LLC leads the comparable SEC ownership view at 7.2%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ARK Investment Management LLC's linked filing trail.

Comparable ownership Top 5

ARK Investment Management LLC 7.2%

BlackRock, Inc. 7.2%

STATE STREET CORP 5.5%

BAILLIE GIFFORD & CO 4.6%

RA CAPITAL MANAGEMENT, L.P. 2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
ARK Investment Management LLC	13D/G 13F Company 13D/G 13F	7.2%	$152,625,941 37,316,856 shares	+$20,329,177	31 Dec 2025
BlackRock, Inc.	13F 13D/G Company 13F 13D/G	7.2% from 13D/G	$132,600,379 43,192,306 shares	—	31 Mar 2026
STATE STREET CORP	13F 13D/G Company · STATE STREET CORPORATION 13F 13D/G	5.5% from 13D/G	$87,466,259 28,490,638 shares	—	31 Mar 2026
BAILLIE GIFFORD & CO	13D/G 13F Company 13D/G 13F	4.6%	$97,239,635 23,774,972 shares	$0	31 Dec 2025
RA CAPITAL MANAGEMENT, L.P.	13D/G 13D/G	2%	$44,187,549 7,725,096 shares	$0	31 Dec 2024
David Hallett	3/4/5 Chief Scientific Officer 3/4/5	0.2%	$3,286,416 1,070,494 shares	—	15 May 2026
VANGUARD PORTFOLIO MANAGEMENT LLC	13F Company 13F	4.3%	$69,870,437 22,759,100 shares	—	31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC	13F Company 13F	4.2%	$68,290,268 22,244,387 shares	—	31 Mar 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$12,907,078.

Buys

Insiders: 0

Sells

$12,907,078

Insiders: 5

Net

-$12,907,078

Shares: -2,858,214

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 0 Shares: 2,858,214

Window (months)	Sell shares	Buy value	Sell value	Net value
0-3	357,974	$0	$1,210,186	-$1,210,186
3-6	841,063	$0	$3,375,763	-$3,375,763
6-9	804,403	$0	$3,899,992	-$3,899,992
9-12	854,774	$0	$4,421,137	-$4,421,137

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 23 reporting-owner rows connected to RECURSION PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

Lux Ventures IV, L.P.

Net 12M change

-$12,907,078

Latest report

15 Jun 2026

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Lux Ventures IV, L.P.	Former 10% Owner	$137,710,376			Mixed	07 Dec 2021
Mubadala Investment Co PJSC	10%+ Owner	$137,333,970			Mixed	02 Mar 2023
Zachary Bogue	Director, 10%+ Owner	$39,514,048			Mixed	03 Jul 2023
Blake Borgeson	Director	$22,705,095	-$3,741,800	-14%	Filing P/S	02 Jun 2026
MIC Capital Partners (Public) Parallel Cayman, LP	10%+ Owner	$14,688,335			Mixed	01 Nov 2021
Dean Y. Li	Director	$13,187,001			Mixed	01 Apr 2026
Michael Secora	Chief Financial Officer	$9,186,510			Mixed	15 Nov 2024
Najat Khan	CEO and President, Director	$7,790,655	-$929,884	-11%	Filing P/S	05 Jun 2026
Ben R. Taylor	Chief Financial Officer	$3,382,759	-$157,704	-4.5%	Median	15 Jun 2026
David Hallett	Chief Scientific Officer	$3,286,416			Median	15 May 2026
Christopher Gibson	Director	$3,199,120	-$8,062,164	-72%	Filing P/S	05 Jun 2026
Tina Marriott	President and COO	$3,129,811			Mixed	15 Nov 2024
Shafique Virani	Chief Business Officer	$1,446,192			Mixed	16 Jan 2024
David J. Mauro	Chief Medical Officer	$1,392,024			Mixed	15 Nov 2024
Ramona Doyle	Chief Medical Officer	$1,280,811			Mixed	16 May 2022
Zavain Dar	Director	$602,174			Mixed	01 Apr 2026
Franziska Michor	Director	$565,385			Mixed	18 Jun 2025
CHAVEZ R. MARTIN	Director	$529,780			Mixed	01 Apr 2024
Terry-Ann Burrell	Director	$514,098			Mixed	01 Jul 2024
Robert Hershberg	Director	$328,107			Mixed	18 Jun 2025

Recent insider transactions for RECURSION PHARMACEUTICALS, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
Ben R. Taylor	RXRX	Class A Common Stock	Tax liability	-0.49%			-5,396	1,101,876	15 Jun 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Sale	-4.33%	$144,800	$3.62	-40,000	883,735	05 Jun 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	4.53%			40,000	923,735	05 Jun 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-0.93%			-40,000	4,263,334	05 Jun 2026	Direct
Najat Khan	RXRX	Class A Common Stock	Sale	-1.07%	$84,459	$3.58	-23,588	2,175,796	05 Jun 2026	Direct
Namandje Bumpus	RXRX	Class A Common Stock	Sale	-9.22%	$15,526	$3.54	-4,386	43,171	03 Jun 2026	Direct
Blake Borgeson	RXRX	Class A Common Stock	Sale	-0.48%	$110,400	$3.68	-30,000	6,169,863	02 Jun 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Sale	-4.33%	$123,200	$3.08	-40,000	883,735	22 May 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	4.53%			40,000	923,735	22 May 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-0.92%			-40,000	4,303,334	22 May 2026	Direct
David Hallett	RXRX	Class A Common Stock	Tax liability	-2.43%			-26,657	1,070,494	15 May 2026	Direct
Najat Khan	RXRX	Class A Common Stock	Tax liability	-2.77%			-62,701	2,199,384	15 May 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Tax liability	-2.52%			-22,821	883,735	15 May 2026	Direct
Ben R. Taylor	RXRX	Class A Common Stock	Tax liability	-2.21%			-25,018	1,107,272	15 May 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Gift	-2.16%			-20,000	906,556	07 May 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Sale	-4.14%	$134,800	$3.37	-40,000	926,556	07 May 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	6.62%			60,000	966,556	07 May 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-1.36%			-60,000	4,343,334	07 May 2026	Direct
Blake Borgeson	RXRX	Class A Common Stock	Sale	-0.48%	$105,600	$3.52	-30,000	6,199,863	05 May 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Sale	-4.23%	$144,400	$3.61	-40,000	906,556	22 Apr 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	4.41%			40,000	946,556	22 Apr 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-0.9%			-40,000	4,403,334	22 Apr 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Sale	-4.23%	$124,000	$3.10	-40,000	906,556	07 Apr 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	4.41%			40,000	946,556	07 Apr 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-0.89%			-40,000	4,443,334	07 Apr 2026	Direct
Blake Borgeson	RXRX	Class A Common Stock	Sale	-0.48%	$93,000	$3.10	-30,000	6,229,863	07 Apr 2026	Direct
Ben R. Taylor	RXRX	Class A Common Stock	Tax liability	-4.07%			-48,028	1,132,290	06 Apr 2026	Direct
Zavain Dar	RXRX	Class A Common Stock	Award	3.44%			4,902	147,231	01 Apr 2026	Direct
Dean Y. Li	RXRX	Class A Common Stock	Award	0.26%			3,268	1,244,177	01 Apr 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Sale	-4.23%	$130,000	$3.25	-40,000	906,556	23 Mar 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	4.41%			40,000	946,556	23 Mar 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-0.88%			-40,000	4,483,334	23 Mar 2026	Direct
Ben R. Taylor	RXRX	Class A Common Stock	Sale	-0.67%	$26,971	$3.39	-7,956	1,180,318	17 Mar 2026	Direct
Ben R. Taylor	RXRX	Class A Common Stock	Tax liability	-0.59%			-7,075	1,188,274	16 Mar 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Gift	-2.16%			-20,000	906,556	09 Mar 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	2.21%			20,000	926,556	09 Mar 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-0.44%			-20,000	4,523,334	09 Mar 2026	Direct
Najat Khan	RXRX	Class A Common Stock	Sale	-1.24%	$94,660	$3.35	-28,298	2,262,085	09 Mar 2026	Direct
Blake Borgeson	RXRX	Class A Common Stock	Sale	-2.64%	$588,200	$3.46	-170,000	6,259,863	03 Mar 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Sale	-4.23%	$138,400	$3.46	-40,000	906,556	19 Feb 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Conversion of derivative security	4.41%			40,000	946,556	19 Feb 2026	Direct
Christopher Gibson	RXRX	Class B Common Stock	Conversion of derivative security	-0.87%			-40,000	4,543,334	19 Feb 2026	Direct
Ben R. Taylor	RXRX	Class A Common Stock	Sale	-1.11%	$41,352	$3.08	-13,426	1,195,349	18 Feb 2026	Direct
David Hallett	RXRX	Class A Common Stock	Tax liability	-1.07%			-11,908	1,097,151	17 Feb 2026	Direct
Christopher Gibson	RXRX	Class A Common Stock	Tax liability	-2.92%			-27,265	906,556	17 Feb 2026	Direct
Ben R. Taylor	RXRX	Class A Common Stock	Tax liability	-0.98%			-11,908	1,208,775	17 Feb 2026	Direct
Najat Khan	RXRX	Class A Common Stock	Tax liability	-0.62%			-14,280	2,290,383	17 Feb 2026	Direct
Najat Khan	RXRX	Class A Common Stock	Tax liability	-0.45%			-10,364	2,304,663	06 Feb 2026	Direct
Najat Khan	RXRX	Class A Common Stock	Award	278.8%			1,703,892	2,315,027	06 Feb 2026	Direct
Ben R. Taylor	RXRX	Class A Common Stock	Tax liability	-0.93%			-11,400	1,220,683	06 Feb 2026	Direct

^* marks a reported price that did not pass the local price check.